Europa Advisors

You've decided to expand into Europe. Now the hard part.

Most SMB life sciences companies make the EU expansion decision at the strategic level and then discover the execution gap. The regulatory work is the obvious challenge. Less obvious: computerized system validation under Annex 11, NIS2 cybersecurity obligations, GDPR operationalization, supplier qualification, pharmacovigilance infrastructure, clinical trial logistics, employment and HR law in a new jurisdiction, country-specific requirements that sit below EU-level frameworks, and access to regional CDMOs, incubators, government funding programs, and VC/PE firms that specialize in EU expansion capital.

The list is the argument. EU expansion touches more domains than most lean organizations have planned for — and the gaps that matter most tend to surface at the worst possible moment.

Our job is to map the terrain. We help organizations get ahead of the known unknowns and reduce the unknown unknowns. We assess readiness across all relevant domains. Where you're covered, we move on. Where you're not, we bring in the right expertise — from within our team or our EU partner network.

Some organizations come to us still stress-testing the decision — assessing regulatory risk, estimating compliance burden, pressure-checking the business case. That's a legitimate starting point. But the core of what we do is execution support for companies that have committed and need cross-domain depth they don't have on staff.